全球乾性老齡化黃斑部病變市場：各地區及國家分析與預測（2025-2035）

乾性老齡化黃斑部病變是進行性眼疾，會影響黃斑部（視網膜的中心），損害負責清晰中央視力的區域。

這種疾病會導致中央視野視力逐漸喪失，而中央視野對於閱讀、駕駛和識別人臉等日常活動至關重要。

由於幾個關鍵因素，乾性老齡化黃斑部病變市場正在經歷強勁成長。主要促進因素之一是全球人口老化。老齡化是導致乾性老齡化黃斑部病變最重要的風險因素，隨著老年人口的增加，對有效治療方法和診斷工具的需求也在增加。此外，光同調斷層掃瞄（OCT）和眼底照相等視網膜成像診斷技術的進步使得能夠更早發現疾病並更準確地了解進展，從而促進了市場的擴張。

此外，人們對精準醫療和基因檢測的興趣日益濃厚，預計將透過針對每位患者量身定做治療方案來改善臨床療效。此外，人們眼部健康意識的增強、生活習慣的改善以及定期眼部檢查等預防措施的擴大也推動了需求。此外，新興國家醫療基礎設施的改善和眼科醫生專業培訓的普及也促進了創新治療方法的引入。這些因素結合起來，預計將繼續推動乾性老齡化黃斑部病變市場的成長。

本報告調查了全球乾性老齡化黃斑部病變市場，並總結了主要趨勢、影響市場的因素分析、法律制度、技術和專利趨勢、案例研究、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章全球乾性老齡化黃斑部病變市場：產業展望

• 市場趨勢
• 法律規範
• 乾性老齡化黃斑部病變的全球流行病學
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 全球乾性老齡化黃斑部病變市場（按地區）

• 北美洲
• 歐洲
• 亞太地區
  • 主要發現
  • 市場動態
  • 市場規模及預測

3. 全球乾性老齡化黃斑部病變市場：競爭格局與公司概況

• 關鍵發展和策略
• 公司簡介
  • AstraZeneca
  • Astellas Pharma
  • Novartis AG.
  • Apellis Pharmaceuticals
  • Alkeus Pharmaceuticals.
  • Belite Bio.
  • Aviceda Therapeutics
  • Cognition Therapeutics
  • Annexon Biosciences
  • Lineage Cell Therapeutics

第4章調查方法

Global Dry Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Dry age-related macular degeneration is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. This condition leads to gradual loss of vision, particularly in the central field of view, which is crucial for activities such as reading, driving, and recognizing faces.

The dry age-related macular degeneration market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers is the aging global population, as age is the most significant risk factor for developing dry age-related macular degeneration. With an increasing number of elderly individuals, the demand for effective treatments and diagnostic tools is on the rise. Additionally, advancements in retinal imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are enabling earlier detection and more precise monitoring of disease progression, driving market growth.

Furthermore, the growing focus on precision medicine and genetic testing is enhancing the ability to tailor treatments to individual patients, thus improving clinical outcomes. The increasing awareness of eye health and the rising adoption of preventive measures, such as lifestyle changes and regular eye screenings, are also stimulating demand. Moreover, the improvement in healthcare infrastructure in emerging markets and the availability of specialized training for ophthalmologists are fuelling the adoption of innovative AMD treatment options. The combination of these drivers is poised to continue supporting the growth of the dry AMD market.

Despite the positive growth trajectory, several challenges continue to impact the global dry age-related macular degeneration market. One of the primary challenges is the high cost of treatment and diagnostic technologies can be a significant barrier. Innovative treatments, especially in the realm of gene therapy, stem cell therapy, and advanced imaging technologies, come with high development and implementation costs. This can limit access to effective therapies in low- and middle-income regions, where healthcare infrastructure may be less developed and resources are limited.

Moreover, lack of effective treatments for the advanced stages of dry AMD. While there are interventions to manage early stages, such as nutritional supplements and lifestyle modifications, there is no cure or approved treatment that can significantly reverse the damage once it progresses to advanced dry AMD or geographic atrophy. This limitation has restricted the market potential for advanced therapies and treatment options.

As the dry age-related macular degeneration market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The increasing development of innovative treatments, such as gene therapies, retinal implants, and biologic agents targeting disease progression, is poised to provide new hope for patients. Furthermore, advancements in diagnostic technologies, including high-resolution imaging and artificial intelligence-driven tools for early detection, will allow for more precise monitoring and intervention. With the aging global population, particularly in regions with a higher prevalence of AMD, the demand for cost-effective, easy-to-administer, and efficient treatment options will continue to rise. Additionally, increased focus on the role of lifestyle modifications, such as diet and supplements, will shape prevention strategies, offering a holistic approach to managing age-related macular degeneration.

In conclusion, the global dry age-related macular degeneration market is expected to experience steady growth, driven by advancements in therapeutic interventions, heightened awareness, and a focus on early detection. As research and development in this space continue to progress, key stakeholders, including pharmaceutical companies, healthcare providers, and researchers, will play a critical role in improving treatment outcomes and patient quality of life. The market's expansion, coupled with continued innovation, will empower patients with better management tools, reducing the long-term burden of the condition and preserving vision for millions around the world.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Dry Age-Related Macular Degeneration Markets: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology of Dry AMD
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Dry Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Dry Age-Related Macular Degeneration Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Dry Age-Related Macular Degeneration Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Dry Age-Related Macular Degeneration Market, by Country
      • 2.3.3.1.1 Japan

3. Global Dry Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles

• 3.1 Key Development and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 AstraZeneca
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Target Customers/End-Users
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Astellas Pharma
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Target Customers/End-Users
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Novartis AG.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Target Customers/End-Users
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 Apellis Pharmaceuticals
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Target Customers/End-Users
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View
  • 3.2.5 Alkeus Pharmaceuticals.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Target Customers/End-Users
    • 3.2.5.4 Key Personnel
    • 3.2.5.5 Analyst View
  • 3.2.6 Belite Bio.
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Target Customers/End-Users
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Aviceda Therapeutics
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products / Product Portfolio
    • 3.2.7.3 Target Customers/End-Users
    • 3.2.7.4 Key Personnel
    • 3.2.7.5 Analyst View
  • 3.2.8 Cognition Therapeutics
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products / Product Portfolio
    • 3.2.8.3 Target Customers/End-Users
    • 3.2.8.4 Key Personnel
    • 3.2.8.5 Analyst View
  • 3.2.9 Annexon Biosciences
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products / Product Portfolio
    • 3.2.9.3 Target Customers/End-Users
    • 3.2.9.4 Key Personnel
    • 3.2.9.5 Analyst View
  • 3.2.10 Lineage Cell Therapeutics
    • 3.2.10.1 Overview
    • 3.2.10.2 Top Products / Product Portfolio
    • 3.2.10.3 Target Customers/End-Users
    • 3.2.10.4 Key Personnel
    • 3.2.10.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Dry Age-Related Macular Degeneration Market, Market Overview
• Figure: Epidemiology of Dry Age-Related Macular Degeneration
• Figure: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023 and 2035
• Figure: Global Dry Age-Related Macular Degeneration Market Coverage
• Figure: Global Dry Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Dry Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Dry Age-Related Macular Degeneration Market, Clinical Trial Analysis,
• Table: Global Dry Age-Related Macular Degeneration Market Dynamics, Impact Analysis
• Table: Global Dry Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035